Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 91-97

  Span, P N ^a   Pollakis, G ^b,c   Paxton, W A ^b,c   Sweep, F C G J ^a   Foekens, J A ^d   Martens, J W M ^d   Sieuwerts, A M ^d   Van Laarhoven, H W M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

breast neoplasms; chemokine receptors; prognosis

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CCR5 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FRAMESHIFT MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; NETHERLANDS; POSTMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; WILD TYPE; BREAST NEOPLASMS; GENE DELETION; GENETICS; INFANT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEWBORN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FRAMESHIFT MUTATION; GENETIC ASSOCIATION STUDIES; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POSTMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CCR5; RETROSPECTIVE STUDIES; SEQUENCE DELETION; YOUNG ADULT;

EID: 84925282909     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28962     Document Type: Article

References (21)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, et al., Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 432-44.
2. Goncalves R, Bose R,. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013; 11: 174-82.
3. Aldinucci D, Colombatti A,. The inflammatory chemokine CCL5 and cancer progression. Mediat Inflamm 2014; 2014: 12.
4. Lin S, Wan S, Sun L, et al., Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci 2012; 103: 904-12.
5. Liu R, Paxton WA, Choe S, et al., Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
6. Benkirane M, Jin DY, Chun RF, et al., Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 1997; 272: 30603-6.
7. Samson M, Libert F, Doranz BJ, et al., Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
8. Huang Y, Paxton WA, Wolinsky SM, et al., The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-3.
9. Paxton WA, Neumann AU, Kang S, et al., RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 2001; 183: 1678-81.
10. Velasco-Velázquez M, Jiao X, De La Fuente M, et al., CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72: 3839-50.
11. Velasco-Velázquez M1, Pestell RG,. The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013; 2: e23660.
12. Meanwell NA, Kadow JF,. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs 2007; 8: 669-81.
13. Mañes S, Mira E, Colomer R, et al., CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003; 198: 1381-9.
14. Foekens JA, Portengen H, van Putten WL, et al., Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989; 49: 5823-8.
15. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, et al., Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009; 27: 542-9.
16. Abu-Taha M, Rius C, Hermenegildo C, et al., Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol 2009; 183: 1393-402.
17. Hartmann MC, Dwyer RM, Costello M, et al., Relationship between CCL5 and transforming growth factor-β1 (TGFβ1) in breast cancer. Eur J Cancer 2011; 47: 1669-75.
18. Zhang Y, Meng FY, Li WL, et al., Association of chemotactic factor receptor 5 gene with breast cancer. Genet Mol Res 2013; 12: 5289-300.
19. Boesecke C, Pett SL,. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS 2012; 7: 456-62.
20. Degerli N, Yilmaz E, Bardakci F,. The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 2005; 38: 248-52.
21. Zafiropoulos A, Crikas N, Passam AM, et al., Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004; 41: e59.